



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

December 2014





HIV/AIDS Drug Treatment Program

Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.682.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

December 2014

N = 6774



Health Authority	Male	Female	All
FRASER	1214	356	1570
INTERIOR	314	92	406
NORTHERN	123	82	205
VANCOUVER COASTAL	3287	449	3736
VANCOUVER ISLAND	605	146	751
	5543	1125	6668
		Unknown/not stated:	106
		Total:	6774

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2009 - December 2014)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2009 - December 2014)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (December 2009 - December 2014)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (December 2009 - December 2014)






1.6 Percent Distribution of Active Participants by CD4 Count (December 2009 - December 2014)






1.7 Percent Distribution of Inactive Participants by CD4 Count (December 2009 - December 2014)





1.8 Active and Inactive Participants (December 2009 - December 2014)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (December 2009 - December 2014)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (December 2009 - December 2014)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(December 2009 - December 2014)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (December 2009 - December 2014)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(December 2009 - December 2014)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (December 2009 - December 2014)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(December 2009 - December 2014)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (December 2009 - December 2014)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(December 2009 - December 2014)






1.18 Baseline CD4 for Antiretroviral First Starts (December 2009 - December 2014)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(December 2009 - December 2014)**






1.20 Cumulative Resistance Testing Results by Resistance Category (December 2009 - December 2014)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (December 2009 - December 2014)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2014
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	680	5	<40	4
1988	22	7	0	7	7	490	7	<40	4
1989	21	58	2	60	55	510	58	<40	4
1990	20	62	1	63	58	510	62	<40	4
1991	21	38	3	41	35	610	40	<40	4
1992	20	69	7	76	60	540	76	<40	4
1993	19	148	16	164	146	570	161	<40	4
1994	18	101	12	113	95	580	110	<40	4
1995	18	128	25	153	129	560	146	<40	4
1996	16	379	64	443	389	560	426	<40	4
1997	14	311	40	351	313	600	340	<40	3
1998	13	223	48	271	220	555	253	<40	3
1999	13	187	44	231	191	540	217	<40	3
2000	14	139	38	177	150	575	170	<40	3
2001	13	137	40	177	147	550	173	<40	3
2002	12	144	29	173	144	540	161	<40	3
2003	11	181	36	217	191	590	212	<40	3
2004	10	186	48	234	204	555	226	<40	3
2005	9	214	54	268	229	550	258	<40	4
2006	8	226	50	276	227	540	263	<40	3
2007	7	291	59	350	293	580	338	<40	3
2008	6	329	82	411	344	600	390	<40	3
2009	5	350	72	422	358	620	406	<40	3
2010	4	327	77	404	340	620	393	<40	3
2011	3	387	84	471	399	610	452	<40	3
2012	3	326	70	396	336	630	382	<40	3
2013	2	311	76	387	324	630	375	<40	3
2014	1	355	66	421	376	585	411	<40	4
Total:		5619	1143	6762					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2013	6296	746	2410	<40	2174	520
FEB-2013	6298	751	1949	<40	1702	530
MAR-2013	6280	759	1901	<40	1709	510
APR-2013	6345	763	2182	<40	1938	530
MAY-2013	6364	753	2149	<40	1901	530
JUN-2013	6387	754	1944	<40	1726	536
JUL-2013	6430	756	2148	<40	1923	520
AUG-2013	6434	769	1994	<40	1734	530
SEP-2013	6439	777	2054	<40	1836	550
OCT-2013	6457	781	2195	<40	1945	530
NOV-2013	6504	781	1926	<40	1704	540
DEC-2013	6525	785	1800	<40	1586	560
JAN-2014	6557	785	2429	<40	2147	560
FEB-2014	6570	785	1895	<40	1655	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6612	790	2126	<40	1870	560
MAY-2014	6679	769	2119	<40	1887	560
JUN-2014	6648	784	1994	<40	1766	550
JUL-2014	6686	780	2179	<40	1927	550
AUG-2014	6705	775	2026	<40	1797	570
SEP-2014	6736	770	2285	<40	1986	550
OCT-2014	6770	763	2251	<40	1917	570
NOV-2014	6766	761	1924	<40	1651	580
DEC-2014	6774	766	1842	<40	1619	580

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2013	1388	2222	111	3811	85	380
FEB-2013	1408	2139	95	5364	81	361
MAR-2013	1442	2002	93	1216	75	340
APR-2013	1398	2181	107	2091	86	345
MAY-2013	1408	2138	88	1857	73	390
JUN-2013	1390	2281	73	1205	66	410
JUL-2013	1388	2292	88	17614	81	300
AUG-2013	1414	2168	85	375	78	440
SEP-2013	1434	2138	92	1832	72	355
OCT-2013	1431	2173	105	542	92	400
NOV-2013	1414	2246	93	240	86	350
DEC-2013	1419	2247	71	1296	50	390
JAN-2014	1418	2266	100	6683	76	285
FEB-2014	1439	2213	73	496	67	490
MAR-2014	1441	2179	115	3890	98	340
APR-2014	1450	2161	112	128	90	400
MAY-2014	1420	2338	90	617	76	350
JUN-2014	1473	2079	96	423	82	380
JUL-2014	1465	2124	95	982	76	355
AUG-2014	1459	2183	88	249	73	370
SEP-2014	1455	2213	103	1031	89	400
OCT-2014	1440	2324	84	257	61	400
NOV-2014	1455	2258	72	3945	60	400
DEC-2014	1483	2202	87	652	66	365

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2013	6270	1388	13	38	141	127	37	11044
FEB-2013	6278	1408	2	32	110	128	8	11080
MAR-2013	6252	1442	13	27	121	159	-26	11108
APR-2013	6321	1398	6	28	186	138	70	11141
MAY-2013	6339	1408	9	39	136	145	18	11186
JUN-2013	6372	1390	6	24	138	122	33	11213
JUL-2013	6407	1388	10	42	130	121	35	11265
AUG-2013	6408	1414	8	37	114	139	1	11307
SEP-2013	6411	1434	11	35	125	143	3	11347
OCT-2013	6431	1431	8	24	156	148	20	11378
NOV-2013	6479	1414	7	23	172	138	48	11418
DEC-2013	6504	1419	6	28	154	148	25	11458
JAN-2014	6539	1418	2	30	144	136	35	11501
FEB-2014	6548	1439	9	40	139	159	9	11545
MAR-2014	6573	1441	9	36	151	146	25	11589
APR-2014	6588	1450	5	27	159	160	15	11625
MAY-2014	6648	1420	14	38	191	151	60	11675
JUN-2014	6623	1473	7	26	142	183	-25	11715
JUL-2014	6664	1465	8	34	176	159	41	11759
AUG-2014	6688	1459	6	18	165	151	24	11791
SEP-2014	6723	1455	2	25	170	157	35	11830
OCT-2014	6752	1440	7	22	161	145	29	11858
NOV-2014	6750	1455	9	20	134	146	-2	11882
DEC-2014	6762	1483	4	40	136	156	12	11931

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2013	52	5754	404	86	6296	0.83%	91.39%	6.42%	1.37%	100.00%
FEB-2013	51	5756	404	87	6298	0.81%	91.39%	6.41%	1.38%	100.00%
MAR-2013	52	5745	403	80	6280	0.83%	91.48%	6.42%	1.27%	100.00%
APR-2013	56	5801	410	78	6345	0.88%	91.43%	6.46%	1.23%	100.00%
MAY-2013	54	5820	415	75	6364	0.85%	91.45%	6.52%	1.18%	100.00%
JUN-2013	57	5844	408	78	6387	0.89%	91.50%	6.39%	1.22%	100.00%
JUL-2013	54	5881	420	75	6430	0.84%	91.46%	6.53%	1.17%	100.00%
AUG-2013	53	5892	420	69	6434	0.82%	91.58%	6.53%	1.07%	100.00%
SEP-2013	50	5904	415	70	6439	0.78%	91.69%	6.45%	1.09%	100.00%
OCT-2013	46	5927	420	64	6457	0.71%	91.79%	6.50%	0.99%	100.00%
NOV-2013	47	5977	412	68	6504	0.72%	91.90%	6.33%	1.05%	100.00%
DEC-2013	48	6000	410	67	6525	0.74%	91.95%	6.28%	1.03%	100.00%
JAN-2014	47	6025	414	71	6557	0.72%	91.89%	6.31%	1.08%	100.00%
FEB-2014	50	6034	418	68	6570	0.76%	91.84%	6.36%	1.04%	100.00%
MAR-2014	50	6054	424	70	6598	0.76%	91.76%	6.43%	1.06%	100.00%
APR-2014	46	6068	422	76	6612	0.70%	91.77%	6.38%	1.15%	100.00%
MAY-2014	46	6141	418	74	6679	0.69%	91.94%	6.26%	1.11%	100.00%
JUN-2014	47	6113	417	71	6648	0.71%	91.95%	6.27%	1.07%	100.00%
JUL-2014	46	6152	415	73	6686	0.69%	92.01%	6.21%	1.09%	100.00%
AUG-2014	46	6173	414	72	6705	0.69%	92.07%	6.17%	1.07%	100.00%
SEP-2014	49	6190	426	71	6736	0.73%	91.89%	6.32%	1.05%	100.00%
OCT-2014	44	6217	436	73	6770	0.65%	91.83%	6.44%	1.08%	100.00%
NOV-2014	46	6226	424	70	6766	0.68%	92.02%	6.27%	1.03%	100.00%
DEC-2014	43	6234	423	74	6774	0.63%	92.03%	6.24%	1.09%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2013	9 20%	2292 37%	9 20%	1870 31%	0 0%	160 3%	0 0%	31 1%	0 0%	29 0%	36 80%	3686 60%	36 80%	4146 68%
FEB-2013	5 14%	2299 38%	3 8%	1877 31%	2 6%	159 3%	0 0%	31 1%	0 0%	28 0%	31 86%	3680 60%	31 86%	4138 68%
MAR-2013	4 14%	2288 38%	3 11%	1871 31%	0 0%	156 3%	0 0%	30 0%	0 0%	28 0%	24 86%	3673 60%	25 89%	4121 68%
APR-2013	3 9%	2307 37%	2 6%	1897 31%	0 0%	154 3%	0 0%	29 0%	0 0%	23 0%	30 91%	3717 60%	30 91%	4156 67%
MAY-2013	6 13%	2310 37%	6 13%	1897 31%	0 0%	151 2%	0 0%	30 0%	0 0%	23 0%	39 87%	3744 61%	39 87%	4175 68%
JUN-2013	2 8%	2300 37%	1 4%	1890 31%	0 0%	147 2%	0 0%	29 0%	0 0%	23 0%	24 92%	3761 61%	24 92%	4197 68%
JUL-2013	12 23%	2331 37%	8 15%	1921 31%	3 6%	150 2%	0 0%	31 0%	0 0%	22 0%	40 77%	3787 61%	40 77%	4217 68%
AUG-2013	7 17%	2325 37%	6 14%	1925 31%	1 2%	151 2%	0 0%	29 0%	0 0%	21 0%	35 83%	3776 61%	35 83%	4201 67%
SEP-2013	5 13%	2329 37%	5 13%	1931 31%	1 3%	145 2%	0 0%	28 0%	0 0%	18 0%	35 88%	3791 61%	35 88%	4211 67%
OCT-2013	3 10%	2347 37%	2 6%	1952 31%	0 0%	143 2%	0 0%	26 0%	0 0%	17 0%	28 90%	3792 61%	29 94%	4205 67%
NOV-2013	7 18%	2348 37%	5 13%	1957 31%	1 3%	143 2%	0 0%	24 0%	0 0%	16 0%	32 82%	3836 61%	33 85%	4251 67%
DEC-2013	9 23%	2353 37%	8 21%	1968 31%	1 3%	138 2%	0 0%	26 0%	0 0%	17 0%	30 77%	3849 61%	30 77%	4257 67%
JAN-2014	8 19%	2382 37%	7 17%	1995 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3864 61%	36 86%	4271 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3881 61%	37 84%	4287 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3905 61%	33 92%	4302 67%
MAY-2014	17 34%	2435 38%	16 32%	2059 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3931 61%	33 66%	4327 67%
JUN-2014	8 20%	2432 38%	9 23%	2064 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	31 78%	3910 61%	31 78%	4298 67%
JUL-2014	13 30%	2463 38%	11 25%	2096 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3921 60%	32 73%	4301 66%
AUG-2014	7 23%	2475 38%	7 23%	2109 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3914 60%	24 77%	4288 66%
SEP-2014	15 38%	2519 39%	12 31%	2148 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3910 60%	24 62%	4290 66%
OCT-2014	11 39%	2548 39%	10 36%	2175 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 61%	3914 60%	17 61%	4295 65%
NOV-2014	6 25%	2549 39%	6 25%	2184 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3902 59%	19 79%	4275 65%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2014	13 27%	2578 39%	9 18%	2207 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3878 59%	37 76%	4250 65%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2013	0 0%	34 1%	17 85%	2363 66%	2 10%	599 17%	1 5%	570 16%	0 0%	9 0%	0 0%	3 0%	0 0%	38 1%
FEB-2013	1 6%	30 1%	12 67%	2355 66%	4 22%	615 17%	1 6%	556 16%	0 0%	9 0%	0 0%	3 0%	0 0%	38 1%
MAR-2013	0 0%	29 1%	12 100%	2338 66%	0 0%	609 17%	0 0%	542 15%	0 0%	10 0%	0 0%	4 0%	0 0%	36 1%
APR-2013	0 0%	26 1%	9 82%	2332 66%	2 18%	630 18%	0 0%	547 15%	0 0%	10 0%	0 0%	3 0%	0 0%	35 1%
MAY-2013	0 0%	26 1%	10 56%	2339 65%	6 33%	647 18%	2 11%	537 15%	0 0%	9 0%	0 0%	3 0%	0 0%	36 1%
JUN-2013	0 0%	25 1%	4 44%	2340 65%	4 44%	654 18%	1 11%	525 15%	0 0%	8 0%	0 0%	3 0%	0 0%	35 1%
JUL-2013	0 0%	26 1%	17 71%	2355 66%	7 29%	682 19%	0 0%	517 14%	0 0%	8 0%	0 0%	4 0%	0 0%	34 1%
AUG-2013	0 0%	24 1%	17 77%	2342 65%	4 18%	688 19%	1 5%	510 14%	0 0%	8 0%	0 0%	3 0%	0 0%	33 1%
SEP-2013	1 5%	22 1%	11 55%	2307 65%	7 35%	702 20%	1 5%	501 14%	0 0%	9 0%	0 0%	3 0%	0 0%	32 1%
OCT-2013	0 0%	21 1%	8 62%	2301 65%	4 31%	709 20%	1 8%	496 14%	0 0%	9 0%	0 0%	2 0%	0 0%	31 1%
NOV-2013	0 0%	20 1%	8 67%	2307 65%	3 25%	735 21%	1 8%	488 14%	0 0%	7 0%	0 0%	3 0%	0 0%	29 1%
DEC-2013	0 0%	18 1%	13 72%	2301 65%	4 22%	735 21%	1 6%	476 13%	0 0%	8 0%	0 0%	3 0%	0 0%	29 1%
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	740 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	762 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2260 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2251 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	2 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	6 35%	2201 63%	9 53%	831 24%	2 12%	449 13%	0 0%	5 0%	0 0%	2 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2185 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2154 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2142 62%	6 46%	869 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2138 62%	5 50%	891 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2110 62%	2 17%	895 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2013	0	0%	1	0%
FEB-2013	0	0%	1	0%
MAR-2013	0	0%	1	0%
APR-2013	0	0%	1	0%
MAY-2013	0	0%	1	0%
JUN-2013	0	0%	1	0%
JUL-2013	0	0%	1	0%
AUG-2013	0	0%	1	0%
SEP-2013	0	0%	0	0%
OCT-2013	0	0%	0	0%
NOV-2013	0	0%	1	0%
DEC-2013	0	0%	1	0%
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2014	0 0%	13 0%	7 32%	2078 61%	12 55%	922 27%	3 14%	386 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
DEC-2014	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	Delavirdine		Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2013	0 0%	1 0%	13 65%	1406 51%	1 5%	273 10%	1 5%	958 35%	5 25%	130 5%
FEB-2013	0 0%	1 0%	13 81%	1409 51%	0 0%	276 10%	1 6%	967 35%	2 13%	144 5%
MAR-2013	0 0%	1 0%	9 75%	1389 50%	0 0%	274 10%	0 0%	957 35%	3 25%	162 6%
APR-2013	0 0%	1 0%	12 60%	1389 50%	0 0%	282 10%	2 10%	960 34%	6 30%	177 6%
MAY-2013	0 0%	1 0%	14 67%	1375 49%	1 5%	291 10%	0 0%	955 34%	6 29%	189 7%
JUN-2013	0 0%	1 0%	8 73%	1381 49%	1 9%	291 10%	0 0%	944 34%	2 18%	187 7%
JUL-2013	0 0%	0 0%	9 47%	1374 49%	1 5%	300 11%	5 26%	951 34%	4 21%	193 7%
AUG-2013	0 0%	0 0%	12 92%	1350 48%	0 0%	301 11%	0 0%	953 34%	1 8%	192 7%
SEP-2013	0 0%	0 0%	12 80%	1357 48%	0 0%	306 11%	1 7%	956 34%	2 13%	195 7%
OCT-2013	0 0%	0 0%	13 87%	1350 48%	0 0%	299 11%	0 0%	957 34%	2 13%	201 7%
NOV-2013	0 0%	0 0%	13 65%	1344 48%	0 0%	307 11%	2 10%	953 34%	5 25%	213 8%
DEC-2013	0 0%	0 0%	8 50%	1353 48%	0 0%	305 11%	2 13%	946 34%	6 38%	226 8%
JAN-2014	0 0%	0 0%	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	0 0%	0 0%	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	0 0%	0 0%	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	0 0%	0 0%	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	0 0%	0 0%	5 71%	1299 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	0 0%	0 0%	4 44%	1281 46%	1 11%	303 11%	1 11%	926 33%	3 33%	259 9%
JUL-2014	0 0%	0 0%	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	258 9%
AUG-2014	0 0%	0 0%	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	0 0%	0 0%	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	0 0%	0 0%	3 60%	1232 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	0 0%	0 0%	2 100%	1209 45%	0 0%	303 11%	0 0%	911 34%	0 0%	252 9%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.8 Number of Participants on Non-Nucleosides by INGREDIENT (continued)

	Delavirdine		Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2014	0 0%	0 0%	8 62%	1190 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2013	0 0%	2 0%	0 0%	1 0%	0 0%	67 8%	6 100%	818 95%	0 0%	1 0%
FEB-2013	0 0%	2 0%	0 0%	1 0%	1 50%	70 8%	1 50%	822 95%	0 0%	1 0%
MAR-2013	0 0%	2 0%	0 0%	1 0%	1 25%	72 8%	3 75%	831 94%	0 0%	1 0%
APR-2013	0 0%	2 0%	0 0%	1 0%	0 0%	72 8%	3 100%	858 94%	0 0%	1 0%
MAY-2013	0 0%	2 0%	3 43%	9 1%	0 0%	73 8%	4 57%	871 94%	0 0%	1 0%
JUN-2013	0 0%	2 0%	5 56%	25 3%	0 0%	76 8%	4 44%	892 92%	0 0%	1 0%
JUL-2013	0 0%	3 0%	6 55%	53 5%	1 9%	79 8%	4 36%	897 90%	0 0%	1 0%
AUG-2013	0 0%	3 0%	3 50%	73 7%	0 0%	77 8%	3 50%	901 88%	0 0%	2 0%
SEP-2013	0 0%	3 0%	4 80%	93 9%	0 0%	74 7%	1 20%	920 87%	0 0%	2 0%
OCT-2013	0 0%	4 0%	3 100%	105 10%	0 0%	78 7%	0 0%	913 85%	0 0%	3 0%
NOV-2013	0 0%	5 0%	3 38%	116 11%	1 13%	80 7%	4 50%	924 84%	0 0%	3 0%
DEC-2013	0 0%	6 1%	4 67%	131 12%	0 0%	78 7%	2 33%	922 83%	0 0%	3 0%
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	77 6%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	253 17%	0 0%	75 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	75 5%	2 18%	920 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	282 18%	0 0%	74 5%	4 27%	921 58%	0 0%	1 0%
OCT-2014	8 50%	407 25%	6 38%	310 19%	0 0%	71 4%	2 13%	908 55%	0 0%	1 0%
NOV-2014	5 45%	453 27%	5 45%	325 19%	0 0%	70 4%	1 9%	895 53%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT (continued)

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2014	11 65%	499 28%	6 35%	336 19%	0 0%	73 4%	0 0%	891 51%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2013	2581	40.99	2256	35.83	347	5.51	196	3.11	86	1.37	830	13.18
FEB-2013	2566	40.74	2268	36.01	350	5.56	194	3.08	87	1.38	833	13.23
MAR-2013	2547	40.56	2265	36.07	365	5.81	194	3.09	80	1.27	829	13.20
APR-2013	2567	40.46	2292	36.12	374	5.89	186	2.93	78	1.23	848	13.36
MAY-2013	2578	40.51	2290	35.98	383	6.02	186	2.92	75	1.18	852	13.39
JUN-2013	2574	40.30	2290	35.85	407	6.37	190	2.97	78	1.22	848	13.28
JUL-2013	2587	40.23	2288	35.58	432	6.72	186	2.89	75	1.17	862	13.41
AUG-2013	2587	40.21	2280	35.44	448	6.96	186	2.89	69	1.07	864	13.43
SEP-2013	2554	39.66	2284	35.47	483	7.50	184	2.86	70	1.09	864	13.42
OCT-2013	2558	39.62	2288	35.43	493	7.64	189	2.93	64	0.99	865	13.40
NOV-2013	2574	39.58	2303	35.41	510	7.84	188	2.89	68	1.05	861	13.24
DEC-2013	2579	39.52	2318	35.52	522	8.00	189	2.90	67	1.03	850	13.03
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2543	38.46	2288	34.60	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2539	38.01	2276	34.08	739	11.06	193	2.89	74	1.11	858	12.85
JUN-2014	2505	37.68	2248	33.81	782	11.76	183	2.75	71	1.07	859	12.92
JUL-2014	2496	37.33	2236	33.44	840	12.56	191	2.86	73	1.09	850	12.71
AUG-2014	2466	36.78	2232	33.29	891	13.29	186	2.77	72	1.07	858	12.80
SEP-2014	2441	36.24	2221	32.97	947	14.06	187	2.78	71	1.05	869	12.90
OCT-2014	2424	35.81	2191	32.36	1011	14.93	192	2.84	73	1.08	879	12.98
NOV-2014	2426	35.86	2161	31.94	1058	15.64	184	2.72	70	1.03	867	12.81
DEC-2014	2402	35.46	2145	31.67	1103	16.28	185	2.73	74	1.09	865	12.77

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2013	38	3	2	9	12	12	420
FEB-2013	32	6	5	8	8	5	305
MAR-2013	27	4	3	6	8	6	380
APR-2013	28	4	2	8	3	10	320
MAY-2013	39	6	4	10	9	10	340
JUN-2013	24	4	1	0	6	13	550
JUL-2013	42	10	6	9	6	11	243
AUG-2013	37	7	4	11	8	6	295
SEP-2013	35	3	4	10	6	12	380
OCT-2013	24	1	4	5	11	3	399
NOV-2013	23	1	2	7	7	6	380
DEC-2013	28	0	3	4	5	15	510
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	26	3	1	6	7	8	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	22	1	4	7	4	5	300
NOV-2014	20	5	1	1	4	8	460
DEC-2014	40	3	5	7	12	13	406

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2013	9565	2403
FEB-2013	9610	2422
MAR-2013	9624	2428
APR-2013	9677	2464
MAY-2013	9724	2480
JUN-2013	9754	2497
JUL-2013	9814	2524
AUG-2013	9845	2530
SEP-2013	9880	2542
OCT-2013	9927	2570
NOV-2013	9950	2566
DEC-2013	9975	2564
JAN-2014	10030	2581
FEB-2014	10054	2575
MAR-2014	10067	2561
APR-2014	10097	2564
MAY-2014	10121	2558
JUN-2014	10156	2566
JUL-2014	10168	2554
AUG-2014	10217	2588
SEP-2014	10259	2598
OCT-2014	10282	2606
NOV-2014	10317	2629
DEC-2014	10365	2637

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
December 2014

N = 6774

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2014

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2014

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2014

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2014

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2014

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	11	13	7
	50+	18	28	13
	Total HSDA:	29	41	20
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	4	4	2
	35-49	19	25	12
	50+	42	55	33
	Total HSDA:	66	85	48
OKANAGAN	0-19	3	3	2
	20-34	15	16	10
	35-49	95	111	69
	50+	172	251	137
	Total HSDA:	285	381	218
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	14	14	10
	35-49	56	72	41
	50+	86	121	68
	Total HSDA:	162	213	120
Total HA:		542	720	406

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	4
	20-34	33	34	22
	35-49	181	221	129
	50+	318	455	251
Total HA:		542	720	406

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	413	564	314
Female	129	156	92

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	406	52	530	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	5	3
	<5 years	8	7
	Total HSDA:	29	20
KOOTENAY BOUNDARY	10 years or more	32	22
	5 years or more	16	12
	<5 years	18	14
	Total HSDA:	66	48
OKANAGAN	10 years or more	152	110
	5 years or more	70	54
	<5 years	63	54
	Total HSDA:	285	218
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	84	54
	5 years or more	34	31
	<5 years	44	35
	Total HSDA:	162	120
Total HA:		542	406

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	284	196
	5 years or more	125	100
	<5 years	133	110
Total HA:		542	406

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	33	45	13	18
KOOTENAY BOUNDARY	58	104	26	40
OKANAGAN	185	619	70	219
THOMPSON/CARIBOO/SHUSWAP	119	392	43	102
Total:	395	1160	152	379

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	3
KOOTENAY BOUNDARY	12
OKANAGAN	44
THOMPSON/CARIBOO/SHUSWAP	36
Total:	95

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	21	22	14
	35-49	121	133	91
	50+	141	197	115
	Total HSDA:	290	359	225
FRASER NORTH	0-19	22	22	6
	20-34	98	99	84
	35-49	368	422	268
	50+	412	645	338
	Total HSDA:	900	1188	696
FRASER SOUTH	0-19	14	14	6
	20-34	85	86	65
	35-49	347	397	285
	50+	353	537	293
	Unknown	0	1	0
	Total HSDA:	799	1035	649
Total HA:		1989	2582	1570

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	43	43	17
	20-34	204	207	163
	35-49	836	952	644
	50+	906	1379	746
	Unknown	0	1	0
Total HA:		1989	2582	1570

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1498	1979	1214
Female	491	603	356

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1570	49	590	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	133	99
	5 years or more	84	67
	<5 years	73	59
	Total HSDA:	290	225
FRASER NORTH	10 years or more	423	301
	5 years or more	221	173
	<5 years	256	222
	Total HSDA:	900	696
FRASER SOUTH	10 years or more	360	280
	5 years or more	216	183
	<5 years	223	186
	Total HSDA:	799	649
Total HA:		1989	1570

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	916	680
	5 years or more	521	423
	<5 years	552	467
Total HA:		1989	1570

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	119	359	39	72
FRASER NORTH	223	1303	65	243
FRASER SOUTH	197	1116	52	347
Total:	539	2778	156	662

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	170
FRASER NORTH	599
FRASER SOUTH	436
Total:	1205

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	18	18	16
	35-49	86	100	73
	50+	184	302	159
	Total HSDA:	290	422	248
RICHMOND	0-19	8	8	2
	20-34	16	16	15
	35-49	49	52	39
	50+	66	104	54
	Total HSDA:	139	180	110
VANCOUVER	0-19	61	64	10
	20-34	391	400	304
	35-49	1685	2002	1291
	50+	2217	3681	1773
	Total HSDA:	4354	6147	3378
Total HA:	4783	6749	3736	

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	71	74	12
	20-34	425	434	335
	35-49	1820	2154	1403
	50+	2467	4087	1986
Total HA:		4783	6749	3736

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4188	5920	3287
Female	593	827	449

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3736	50	590	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	164	133
	5 years or more	44	39
	<5 years	82	76
	Total HSDA:	290	248
RICHMOND	10 years or more	64	46
	5 years or more	32	24
	<5 years	43	40
	Total HSDA:	139	110
VANCOUVER	10 years or more	2126	1521
	5 years or more	1048	855
	<5 years	1180	1002
	Never on ART	0	0
	Total HSDA:	4354	3378
Total HA:	4783	3736	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2354	1700
	5 years or more	1124	918
	<5 years	1305	1118
	Never on ART	0	0
Total HA:		4783	3736

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	136	351	54	85
RICHMOND	41	260	15	95
VANCOUVER	506	9412	211	5118
Total:	683	10023	280	5298

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	4
RICHMOND	3
VANCOUVER	97
Total:	104

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	15	17	12
	35-49	78	92	66
	50+	140	230	112
	Total HSDA:		235	341
NORTH VANCOUVER ISLAND	0-19	1	1	0
	20-34	11	12	8
	35-49	35	40	30
	50+	52	79	39
	Total HSDA:		99	132
SOUTH VANCOUVER ISLAND	0-19	9	9	1
	20-34	44	46	34
	35-49	214	255	171
	50+	355	552	277
	Total HSDA:		622	862
Total HA:		956	1335	751

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	2
	20-34	70	75	54
	35-49	327	387	267
	50+	547	861	428
Total HA:		956	1335	751

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	772	1082	605
Female	184	253	146

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	751	51	450	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	105	83
	5 years or more	68	58
	<5 years	62	50
	Total HSDA:	235	191
NORTH VANCOUVER ISLAND	10 years or more	47	36
	5 years or more	21	18
	<5 years	31	23
	Total HSDA:	99	77
SOUTH VANCOUVER ISLAND	10 years or more	307	211
	5 years or more	150	126
	<5 years	165	146
	Total HSDA:	622	483
Total HA:		956	751

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	459	330
	5 years or more	239	202
	<5 years	258	219
Total HA:		956	751

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	163	499	84	163
NORTH VANCOUVER ISLAND	107	222	50	66
SOUTH VANCOUVER ISLAND	177	1454	50	510
Total:	447	2175	184	739

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	42
NORTH VANCOUVER ISLAND	29
SOUTH VANCOUVER ISLAND	78
Total:	149

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	5	6	2
	35-49	14	17	5
	50+	13	17	9
	Total HSDA:	33	41	16
NORTH WEST	0-19	2	2	0
	20-34	9	13	8
	35-49	24	35	22
	50+	30	43	22
	Total HSDA:	65	93	52
NORTHERN INTERIOR	0-19	1	1	0
	20-34	27	30	23
	35-49	70	84	60
	50+	70	113	54
	Total HSDA:	168	228	137
Total HA:		266	362	205

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	4	4	0
	20-34	41	49	33
	35-49	108	136	87
	50+	113	173	85
Total HA:		266	362	205

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	164	228	123
Female	102	134	82

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	205	46	480	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	11	6
	5 years or more	9	4
	<5 years	13	6
	Total HSDA:	33	16
NORTH WEST	10 years or more	16	7
	5 years or more	22	20
	<5 years	27	25
	Total HSDA:	65	52
NORTHERN INTERIOR	10 years or more	47	30
	5 years or more	46	43
	<5 years	75	64
	Total HSDA:	168	137
Total HA:		266	205

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	74	43
	5 years or more	77	67
	<5 years	115	95
Total HA:		266	205

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	27	54	4	6
NORTH WEST	58	135	21	29
NORTHERN INTERIOR	93	357	24	173
Total:	178	546	49	208

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	22
NORTHERN INTERIOR	21
Total:	49

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	9	6
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	27	8
	THOMPSON/CARIBOO/SHUSWAP	21	35	16
	Total HA:	45	77	33
FRASER	FRASER EAST	32	39	28
	FRASER NORTH	59	86	43
	FRASER SOUTH	63	89	49
	Total HA:	154	214	120
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	23	42	21
	RICHMOND	8	13	7
	VANCOUVER	486	750	405
	Total HA:	517	805	433
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	41	65	32
	NORTH VANCOUVER ISLAND	11	20	11
	SOUTH VANCOUVER ISLAND	32	66	26
	Total HA:	84	151	69
NORTHERN	NORTH EAST	6	8	3
	NORTH WEST	30	51	26
	NORTHERN INTERIOR	59	86	54
	Total HA:	95	145	83
Total:		895	1392	738

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	564	897	452
Female	331	495	286

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	738	48	460	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: Persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Combination Therapy: using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

Complera (CPL): the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.





Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (DTG): an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

Efavirenz (Sustiva, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

Emtricitabine (FTC): a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

Famciclovir (Famvir): a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (MVC, Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: The net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

Tenofovir (Viread, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Trizivir (TRZ): ViiV Healthcare's trade name for a pill that combines ABACAVIR (ABC), ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

Truvada (TRU): the Gilead trade name for a pill that contains both TENOFOVIR and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

